Clinical Report: Longitudinal Analysis of Plasma Proteomics in Psoriasis

Overview

This study investigates the plasma proteomic changes in psoriasis patients undergoing secukinumab treatment, identifying key inflammatory biomarkers linked to disease severity and treatment response. The findings highlight the potential for using specific proteins as biomarkers for monitoring therapeutic efficacy.

Background

Psoriasis is a chronic inflammatory skin disease driven by the IL-23/IL-17 axis, leading to significant morbidity. Understanding the systemic immune alterations associated with psoriasis and its treatment is crucial for improving patient management and therapeutic outcomes. This study provides insights into the longitudinal changes in inflammatory proteins during IL-17A blockade, which may inform future therapeutic strategies.

Data Highlights

Key Findings

• Baseline plasma profiles distinguished psoriasis patients from healthy controls.
• Key proteins with altered levels included CXCL1, CXCL5, CCL20, and HGF.
• Secukinumab treatment led to a reduction in inflammatory mediators like CCL20 and IL-6.
• IL-17C levels correlated positively with disease severity, indicating its potential as a biomarker.
• Functional enrichment analysis revealed involvement of cytokine signaling pathways in the observed changes.

Clinical Implications

The identification of specific inflammatory biomarkers may enhance the monitoring of treatment responses in psoriasis patients. Clinicians can utilize these biomarkers to tailor therapeutic strategies and improve patient outcomes during secukinumab therapy.

Conclusion

This study underscores the importance of plasma proteomics in understanding the systemic effects of IL-17A blockade in psoriasis, paving the way for future research on biomarkers in inflammatory skin diseases.

References

1. Clinical Rheumatology, 2024 -- Discovery and validation of inflammatory markers in primary Sjögren’s syndrome
2. Journal of Crohn's and Colitis, 2025 -- Analysis of Serum Proteomics to Explore Heterogeneity in Inflammatory Bowel Disease
3. Clinical Rheumatology, 2020 -- Timely Identification of Psoriatic Arthritis in Patients with Psoriasis
4. The New Gastroenterologist, 2025 -- Novel Biomarkers Discovered Linked to Treatment Efficacy in Inflammatory Bowel Disease
5. Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris
6. British Journal of Dermatology, 2023 -- Secukinumab long-term efficacy and safety in psoriasis
7. Living EuroGuiDerm Guideline for the systemic treatment of psoriasis vulgaris
8. Secukinumab long-term efficacy and safety in psoriasis
9. EA DV CONGRESS AMSTERDAM 25-28 SEPTEMBER 2024 EUR